FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588419540> ?p ?o ?g. }

• W2588419540 endingPage "626" @default.
• W2588419540 startingPage "616" @default.
• W2588419540 abstract "Background Dual inhibition of activated MAPK and mTOR signaling pathways may enhance the antitumor efficacy of the MEK 1/2 inhibitor pimasertib and the mTOR inhibitor temsirolimus given in combination. Methods In this phase I study, patients with refractory advanced solid tumors (NCT01378377) received once-weekly temsirolimus plus once-daily oral pimasertib in 21-day cycles in a modified 3 + 3 dose-escalation design. The maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of pimasertib in combination with temsirolimus, safety and pharmacokinetics (PK) were investigated. Results Of 33 patients evaluated, all experienced ≥1 treatment-emergent adverse event (TEAE) and 31 had treatment-related TEAEs, most frequently stomatitis and thrombocytopenia. TEAEs were reversible. No deaths were attributed to treatment. Nine patients had dose-limiting toxicities (stomatitis, thrombocytopenia, serum creatinine phosphokinase increase, visual impairment) and the MTD was determined as 45 mg/day pimasertib plus 25 mg/week temsirolimus. However, due to overlapping toxicities no further investigations were performed and the RP2D was not defined. PK profiles of both agents were not adversely affected. Seventeen patients (17/26 patients) had a best response of stable disease; five had stable disease lasting >12 weeks. Conclusions The RP2D was not defined and the pimasertib plus temsirolimus combination investigated did not warrant further study." @default.
• W2588419540 created "2017-02-24" @default.
• W2588419540 creator A5000961519 @default.
• W2588419540 creator A5005436649 @default.
• W2588419540 creator A5007942018 @default.
• W2588419540 creator A5017201728 @default.
• W2588419540 creator A5028833538 @default.
• W2588419540 creator A5053481267 @default.
• W2588419540 creator A5061237827 @default.
• W2588419540 creator A5071800834 @default.
• W2588419540 creator A5080242644 @default.
• W2588419540 creator A5084295219 @default.
• W2588419540 date "2017-02-13" @default.
• W2588419540 modified "2023-10-18" @default.
• W2588419540 title "Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors" @default.
• W2588419540 cites W1546748481 @default.
• W2588419540 cites W1592490241 @default.
• W2588419540 cites W1602787370 @default.
• W2588419540 cites W1752845679 @default.
• W2588419540 cites W1967913221 @default.
• W2588419540 cites W1970195561 @default.
• W2588419540 cites W1979842614 @default.
• W2588419540 cites W2011509847 @default.
• W2588419540 cites W2012251891 @default.
• W2588419540 cites W2013518349 @default.
• W2588419540 cites W2022415977 @default.
• W2588419540 cites W2028752124 @default.
• W2588419540 cites W2029754521 @default.
• W2588419540 cites W2036614475 @default.
• W2588419540 cites W2036962877 @default.
• W2588419540 cites W2039205618 @default.
• W2588419540 cites W2056854155 @default.
• W2588419540 cites W2069912173 @default.
• W2588419540 cites W2070572192 @default.
• W2588419540 cites W2073025925 @default.
• W2588419540 cites W2091935713 @default.
• W2588419540 cites W2112001957 @default.
• W2588419540 cites W2118169307 @default.
• W2588419540 cites W2120492882 @default.
• W2588419540 cites W2121640179 @default.
• W2588419540 cites W2135131549 @default.
• W2588419540 cites W2136042865 @default.
• W2588419540 cites W2137705897 @default.
• W2588419540 cites W2138401670 @default.
• W2588419540 cites W2148823465 @default.
• W2588419540 cites W2157983986 @default.
• W2588419540 cites W2161299239 @default.
• W2588419540 cites W2162999937 @default.
• W2588419540 cites W2165280661 @default.
• W2588419540 cites W2166335627 @default.
• W2588419540 cites W295765284 @default.
• W2588419540 cites W584714177 @default.
• W2588419540 doi "https://doi.org/10.1007/s10637-017-0442-3" @default.
• W2588419540 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5935457" @default.
• W2588419540 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28194539" @default.
• W2588419540 hasPublicationYear "2017" @default.
• W2588419540 type Work @default.
• W2588419540 sameAs 2588419540 @default.
• W2588419540 citedByCount "20" @default.
• W2588419540 countsByYear W25884195402018 @default.
• W2588419540 countsByYear W25884195402019 @default.
• W2588419540 countsByYear W25884195402020 @default.
• W2588419540 countsByYear W25884195402021 @default.
• W2588419540 countsByYear W25884195402022 @default.
• W2588419540 crossrefType "journal-article" @default.
• W2588419540 hasAuthorship W2588419540A5000961519 @default.
• W2588419540 hasAuthorship W2588419540A5005436649 @default.
• W2588419540 hasAuthorship W2588419540A5007942018 @default.
• W2588419540 hasAuthorship W2588419540A5017201728 @default.
• W2588419540 hasAuthorship W2588419540A5028833538 @default.
• W2588419540 hasAuthorship W2588419540A5053481267 @default.
• W2588419540 hasAuthorship W2588419540A5061237827 @default.
• W2588419540 hasAuthorship W2588419540A5071800834 @default.
• W2588419540 hasAuthorship W2588419540A5080242644 @default.
• W2588419540 hasAuthorship W2588419540A5084295219 @default.
• W2588419540 hasBestOaLocation W25884195402 @default.
• W2588419540 hasConcept C126322002 @default.
• W2588419540 hasConcept C143998085 @default.
• W2588419540 hasConcept C183713625 @default.
• W2588419540 hasConcept C185592680 @default.
• W2588419540 hasConcept C190283241 @default.
• W2588419540 hasConcept C197934379 @default.
• W2588419540 hasConcept C2776820818 @default.
• W2588419540 hasConcept C55493867 @default.
• W2588419540 hasConcept C71924100 @default.
• W2588419540 hasConcept C86554907 @default.
• W2588419540 hasConcept C98274493 @default.
• W2588419540 hasConceptScore W2588419540C126322002 @default.
• W2588419540 hasConceptScore W2588419540C143998085 @default.
• W2588419540 hasConceptScore W2588419540C183713625 @default.
• W2588419540 hasConceptScore W2588419540C185592680 @default.
• W2588419540 hasConceptScore W2588419540C190283241 @default.
• W2588419540 hasConceptScore W2588419540C197934379 @default.
• W2588419540 hasConceptScore W2588419540C2776820818 @default.
• W2588419540 hasConceptScore W2588419540C55493867 @default.
• W2588419540 hasConceptScore W2588419540C71924100 @default.
• W2588419540 hasConceptScore W2588419540C86554907 @default.
• W2588419540 hasConceptScore W2588419540C98274493 @default.

• next